Álvaro Rietmann

Mr. Álvaro Rietmann

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2024 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
Roque SpinelliRoque Spinelli
Roque Spinelli
ÁRÁlvaro Rietmann
Álvaro Rietmann
Ivan SanchisIvan Sanchis
Ivan Sanchis
Hector GoicoecheaHector Goicoechea
Hector Goicoechea
ASAlvaro Sebastian Siano
Alvaro Sebastian Siano

6 February 2025 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
Roque SpinelliRoque Spinelli
Roque Spinelli
Ivan SanchisIvan Sanchis
Ivan Sanchis
ÁRÁlvaro Rietmann
Álvaro Rietmann
MHMaria Veronica Humpola
Maria Veronica Humpola
ASAlvaro Sebastian Siano
Alvaro Sebastian Siano


29 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ÁRÁlvaro Rietmann
Álvaro Rietmann
Ivan SanchisIvan Sanchis
Ivan Sanchis
Roque SpinelliRoque Spinelli
Roque Spinelli
JLJavier Alejandro López
Javier Alejandro López
ASAlvaro Sebastian Siano
Alvaro Sebastian Siano
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder, driving the search for multitarget-directed ligands (MTDLs) able to modulate multiple pathological pathways. Since amphibians represent a rich source of bioactive peptides, skin extracts from Scinax nasicus and Dendropsophus nanus, classified by sex, developmental stage, and season, were evaluated against key AD-related mechanisms, including cholinesterase inhibition, antioxidant activity, and Fe²⁺ chelation. Subsequently, a rational discovery workflow was implemented, integrating extract-level chemical characterization and bioactivity screening with the sequence identification of the main components and a novel in silico algorithm-based prioritization. This strategy, formalized through the development of the Multi-Target Therapeutic Potential Score (MTTP-Score), produced a focused synthetic library while minimizing experimental time and cost. Bioactivity-guided evaluation identified peptides derived from D. nanus (Dn) as displaying the most promising multitarget candidates. Dn-7 combined sub-micromolar dual cholinesterase inhibition (IC50 = 0.32 and 1.2 µM for AChE and BChE, respectively) with highly efficient Fe²⁺ chelation (EC50 = 39 µM), representing the highest MTDL activity reported for an amphibian peptide. Dn-18 emerged as a selective butyrylcholinesterase inhibitor with strong metal chelating capacity. Overall, this study establishes a validated platform for the rational discovery of peptide-based MTDLs for AD.

7 October 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
ÁRÁlvaro Rietmann
Álvaro Rietmann
Ivan SanchisIvan Sanchis
Ivan Sanchis
Roque SpinelliRoque Spinelli
Roque Spinelli
JLJavier Alejandro López
Javier Alejandro López
ASAlvaro Sebastian Siano
Alvaro Sebastian Siano
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder, driving the search for multitarget-directed ligands (MTDLs) able to modulate multiple pathological pathways. Since amphibians represent a rich source of bioactive peptides, skin extracts from Scinax nasicus and Dendropsophus nanus, classified by sex, developmental stage, and season, were evaluated against key AD-related mechanisms, including cholinesterase inhibition, antioxidant activity, and Fe2+ chelation. Subsequently, a rational discovery workflow was implemented, integrating extract-level chemical characterization and bioactivity screening with the sequence identification of the main components and a novel in silico algorithm-based prioritization. This strategy, formalized through the Multi-Target Therapeutic Potential Score (MTTP-Score), served as a rational filter to produce a focused synthetic library, significantly minimizing experimental time and cost. Peptides derived from D. nanus (Dn) displayed the most promising multitarget candidates. Dn-7 combined sub-micromolar dual cholinesterase inhibition (IC50 = 0.32 and 1.2 µM for AChE and BChE, respectively) with highly efficient Fe2+ chelation (EC50 = 39 µM), representing the highest MTDL activity reported for an amphibian peptide. Dn-18 emerged as a moderate butyrylcholinesterase inhibitor with strong metal chelating capacity. Overall, this study establishes a pipeline for the rational discovery of peptide-based MTDL scaffolds for AD.